Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) presented real-world data at the 2026 American Society of Clinical Psychopharmacology Annual Meeting showing that opioid use remains common among U.S. adults diagnosed with fibromyalgia, despite longstanding treatment guidelines discouraging their use. The findings underscore a significant gap between clinical practice and evidence-based recommendations, according to the company.
Based on a retrospective analysis of more than 261,000 patients in the Symphony Health claims database, the study found that approximately 40% of commercially insured, Medicare Advantage and Medicaid patients with fibromyalgia were prescribed at least one opioid. Tramadol and oxycodone were the most common prescriptions. The data highlight the persistent use of opioids in this patient population, even as non-opioid treatment options are available.
Tonix said the findings highlight the need for greater awareness of FDA-approved, non-opioid treatment options, including TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), the company’s recently approved fibromyalgia therapy. TONMYA is the first new treatment for fibromyalgia in more than 15 years. Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need.
The company’s CNS commercial infrastructure supports its marketed products, including its acute migraine products Zembrace SymTouch and Tosymra. Tonix is also maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. In addition, the company’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
For investors, the latest news and updates relating to TNXP are available in the company’s newsroom at https://ibn.fm/TNXP. The full press release can be viewed at https://ibn.fm/6AtjR.
Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.
